The endocannabinoid system (ECS) is an endogenous signalling pathway involved in the control of several gastrointestinal (GI) functions at both peripheral and central levels. In recent years, it has become apparent that the ECS is pivotal in the regulation of GI motility, secretion and sensitivity, but endocannabinoids (ECs) are also involved in the regulation of intestinal inflammation and mucosal barrier permeability, suggesting their role in the pathophysiology of both functional and organic GI disorders. Genetic studies in patients with irritable bowel syndrome (IBS) or inflammatory bowel disease have indeed shown significant associations with polymorphisms or mutation in genes encoding for cannabinoid receptor or enzyme responsible for their catabolism, respectively. Furthermore, ongoing clinical trials are testing EC agonists/antagonists in the achievement of symptomatic relief from a number of GI symptoms. Despite this evidence, there is a lack of supportive RCTs and relevant data in human beings, and hence, the possible therapeutic application of these compounds is raising ethical, political and economic concerns. More recently, the identification of several EC-like compounds able to modulate ECS function without the typical central side effects of cannabinomimetics has paved the way for emerging peripherally acting drugs. This review summarizes the possible mechanisms linking the ECS to GI disorders and describes the most recent advances in the manipulation of the ECS in the treatment of GI diseases.

Endocannabinoid-related compounds in gastrointestinal diseases / Marcella, Pesce; Alessandra, D'Alessandro; Osvaldo, Borrelli; Gigli, Stefano; Seguella, Luisa; Rosario, Cuomo; Esposito, Giuseppe; Giovanni, Sarnelli. - In: JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. - ISSN 1582-4934. - ELETTRONICO. - 22:2(2018), pp. 706-715. [10.1111/jcmm.13359.]

Endocannabinoid-related compounds in gastrointestinal diseases

GIGLI, STEFANO;SEGUELLA, LUISA;ESPOSITO, GIUSEPPE;
2018

Abstract

The endocannabinoid system (ECS) is an endogenous signalling pathway involved in the control of several gastrointestinal (GI) functions at both peripheral and central levels. In recent years, it has become apparent that the ECS is pivotal in the regulation of GI motility, secretion and sensitivity, but endocannabinoids (ECs) are also involved in the regulation of intestinal inflammation and mucosal barrier permeability, suggesting their role in the pathophysiology of both functional and organic GI disorders. Genetic studies in patients with irritable bowel syndrome (IBS) or inflammatory bowel disease have indeed shown significant associations with polymorphisms or mutation in genes encoding for cannabinoid receptor or enzyme responsible for their catabolism, respectively. Furthermore, ongoing clinical trials are testing EC agonists/antagonists in the achievement of symptomatic relief from a number of GI symptoms. Despite this evidence, there is a lack of supportive RCTs and relevant data in human beings, and hence, the possible therapeutic application of these compounds is raising ethical, political and economic concerns. More recently, the identification of several EC-like compounds able to modulate ECS function without the typical central side effects of cannabinomimetics has paved the way for emerging peripherally acting drugs. This review summarizes the possible mechanisms linking the ECS to GI disorders and describes the most recent advances in the manipulation of the ECS in the treatment of GI diseases.
endocannabinoid system; gastrointestinal pathophysiology; functional gastrointestinal disorders; non-alcoholicsteatohepatitis; inflammatory bowel disease
01 Pubblicazione su rivista::01a Articolo in rivista
Endocannabinoid-related compounds in gastrointestinal diseases / Marcella, Pesce; Alessandra, D'Alessandro; Osvaldo, Borrelli; Gigli, Stefano; Seguella, Luisa; Rosario, Cuomo; Esposito, Giuseppe; Giovanni, Sarnelli. - In: JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. - ISSN 1582-4934. - ELETTRONICO. - 22:2(2018), pp. 706-715. [10.1111/jcmm.13359.]
File allegati a questo prodotto
File Dimensione Formato  
Pesce_Endocannabinoid-related_2018.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 299.82 kB
Formato Adobe PDF
299.82 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1012435
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 28
social impact